Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
Valion Bio is advancing Entolimod into a U.S. government-funded therapeutic efficacy study at AFRRI, testing whether post-exposure treatment improves survival in a gastrointestinal acute radiation syndrome model. The study is fully funded by NIAID's Radiation and Nuclear Countermeasures Program, preserving Valion's capital while generating efficacy data; dosing occurs 24 hours after radiation exposure with 30-day survival monitoring.
Key figures
- Drug Name
- Entolimod
- Phase Of Trial
- Therapeutic efficacy phase (animal model, GI-ARS)
- Study funding
- fully funded by NIAID/RNCP via Interagency Agreement with USU/AFRRI
- Topline timing
- early December 2026
- Primary endpoint
- survival, 30-day monitoring
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.